Loading organizations...
Key people at Cidera.
Cidera, originally operating under the name SkyCache, was a Laurel, Maryland-based telecommunications company that provided satellite delivery of Internet content from the network core directly to the edge. The venture-backed firm specialized in cache optimization, Usenet News distribution, and streaming media services tailored specifically for customers across the mobile and telecommunications sectors. During its operational lifespan, the enterprise successfully raised a total of $137 million in venture capital funding, which included a final $75 million venture financing round approximately 24 years ago. The company secured this financial backing from a syndicate of prominent institutional investors, including New Enterprise Associates, The Carlyle Group, GE Equity, and Institutional Venture Partners. Despite surviving the initial dot-com bust, the business ultimately ceased its satellite content delivery services and permanently closed down its corporate operations in 2003. The organization was founded in 1997.
Key people at Cidera.
Cidara Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies to treat serious infectious diseases, particularly fungal infections and influenza, using its proprietary Cloudbreak® platform for drug-Fc conjugates (DFCs). These DFCs combine small molecules or peptides with antibody fragments to inhibit disease targets while engaging the immune system for enhanced potency, extended half-life, and immune clearance.[2][3][4] Headquartered in San Diego, California, with around 73 employees, Cidara targets unmet needs in immunocompromised patients facing high-mortality infections like invasive fungal diseases and influenza complications, aiming to improve outcomes where current treatments fall short due to resistance and limitations.[1][2][5]
The company's mission is to save lives and elevate the standard of care through innovative anti-infectives and antivirals, guided by core values of integrity, accountability, collaboration, urgency, and courage.[2][4][5] Recent growth includes positive Phase 2b results for its influenza prevention candidate CD388, culminating in an acquisition by Merck announced prior to December 2025, which diversifies Merck's portfolio with this long-acting antiviral.[6]
Founded in 2012, Cidara Therapeutics emerged to address critical gaps in antifungal therapies amid rising antibiotic resistance and inadequate treatments for severe infections.[3] The company was established with a focus on infectious diseases, particularly fungal infections threatening immunocompromised patients, building on the need for more effective, well-tolerated options.[1][3] Key leadership includes Jeffrey Stein, Ph.D., as president and CEO, who highlighted the team's dedication in advancing CD388 through pivotal Phase 2b NAVIGATE study results.[6]
Early traction centered on the Cloudbreak platform, enabling novel DFCs to overcome resistance mechanisms, with evolution toward broader applications in viral infections like influenza.[3][4][6] This progression from R&D-focused antifungal development to late-stage antivirals positioned Cidara for its transformative Merck acquisition, marking a pivotal milestone in its journey.[6]
Cidara rides the wave of antimicrobial resistance and demand for next-generation immunotherapies in biotech, where fungal/viral infections contribute to high morbidity in vulnerable populations amid limited treatment options.[1][3] Its timing aligns with post-pandemic emphasis on resilient antiviral strategies and innovative platforms like DFCs, which counter resistance trends threatening global health.[2][6] Market forces favoring Cidara include rising investment in biotech M&A—exemplified by Merck's acquisition to bolster its pipeline—and regulatory pushes for novel anti-infectives.[6]
By pioneering DFCs, Cidara influences the ecosystem through tech transfer to giants like Merck, accelerating commercialization and setting precedents for hybrid small-molecule/antibody therapies in infectious diseases.[4][6]
Post-acquisition by Merck, Cidara's Cloudbreak platform and CD388 will integrate into a global powerhouse, fast-tracking regulatory approval, manufacturing, and market reach for influenza prevention in high-risk groups.[6] Trends like escalating resistance, aging populations, and AI-driven drug design will amplify DFC potential across oncology and other diseases.[2][4] Expect Cidara's influence to evolve from standalone innovator to cornerstone of Merck's growth engine through 2030, delivering transformative outcomes while inspiring similar conjugate platforms industry-wide—reinforcing its legacy in saving lives via targeted immunotherapy.[6]
